BioPharm Insight quotes Konstantin Linnik in “Myriad gene patent decision positive outcome for industry, provides additional clarity on claim construction”Print PDF
Konstantin Linnik, a member of the firm’s Intellectual Property and Life Sciences practice groups, was quoted by BioPharm Insight in “Myriad gene patent decision positive outcome for industry, provides additional clarity on claim construction” on August 22.
The article discusses the recent US Federal Circuit Court of Appeals ruling in the Myriad Genetics case, which provides additional clarity on patent claim composition. The Federal Circuit upheld Myriad’s composition of matter claims covering isolated DNA of BRCA 1 and BRCA 2 genes. The decision by the appeals court reinstates the prior Court decision of July 29, 2011.
“The decision is a positive outcome,” said Konstantin. “If isolated DNA was found not to be patentable, it would have been a huge blow to the industry,” he said.